Our primary goal is to assess only relevant endpoints that have tangible outcomes for cancer patients and clinical practice. Over the previous grant period, QOL research has been organized into a programmatic approach following three themes: 1) assessing QOL endpoints efficiently within treatment trials; 2) designing trials targeted specifically to QOL endpoints; and 3) developing new QOL methodology. Cancer treatment delivery can be improved through direct intervention to impact QOL endpoints, improved QOL assessment methods, or interventions to ameliorate concomitant side effects. A barrier to the development of these research efforts has been the lack of dedicated resources. Preliminary Work: A guiding principle of our preliminary work can be summarized as """"""""less is more"""""""". We demonstrated that a single item global QOL instrument can display greater sensitivity to change than a multi- tem tool aimed at the same construct. We use minimally sufficient sets of individual QOL items and a prior clinically significant effect sizes. Preliminary Work: A guiding principle of our preliminary work can be summarized as """"""""less is more."""""""" We demonstrated that a single item global QOL instrument can display greater sensitivity to change than a multi- item tool aimed at the same construct. We use minimally sufficient sets of individual QOL items and a priori clinically significant effect sizes. Clinical trials work includes pilot studies that target QOL endpoints (such social support) which impact directly on the ability to receive and tolerate cancer treatments and special populations (e.g., the elderly). Methodological advances include new tools, approaches, and analytical methods for combining QOL data with the traditional treatment endpoints of survival and response. This work also impacts the design of and accrual to cancer treatment trials. Future Directions: We have identified major issues for QOL research which will be addressed across all disease committees. We will define clinical significance for QOL endpoints by hosting an international meeting with the purpose of drafting a consensus document. Other research targets the use of individual questions as clinical intervention triggers and the use of proxy respondents to address the issue of missing data. We will construct an assessment package to identify frail elderly cancer patients so that modified treatments can be developed and linkage programs established within the community oncology practices to address deficits in individual patient social support. We will also explore the use of complementary therapies for pain management, including music and massage. Summary: The unique community practice-based structure of NCCTG has fostered the development of efficient, programmatic, and pragmatic, and pragmatic QOL research. We are at a critical juncture whereupon the present activity can be grown into a fully funded and functional program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA025224-23S1
Application #
6665607
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-01-01
Project End
2002-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
23
Fiscal Year
2002
Total Cost
$78,870
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Witzig, T E; LaPlant, B; Habermann, T M et al. (2017) High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood Cancer J 7:e576
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060

Showing the most recent 10 out of 718 publications